Cancer Immunotherapy and Experimental Therapeutics - T32

癌症免疫疗法和实验疗法 - T32

• 批准号: 10208822
• 负责人: Eduardo V Davila
• 金额: $ 31.54万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-08 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10208822
• 关键词: Investigational Therapies; cancer immunotherapy

ABSTRACT A significant advance in cancer, still a major cause of morbidity and mortality in the US, has been the discovery of immune-directed therapy. This is a rapidly changing field that will require future clinician researchers to draw upon a skillset that is quite distinct from current investigation and practice, as host factors take a dominant role over traditional, anatomical-driven parameters. The goal of this proposed T32 program is to train future oncology clinical providers and researchers in the most advanced and promising forms of immune-directed and cell therapy, by integrating those newly required skills into a training plan that addresses those unique needs. New challenges include a multitude of new agents under development, new mechanisms of action, a distinct toxicity profile mostly consisting of immune/autoimmune side effects, and the lack of patient selection or predictive markers for these therapies. The opportunity is to invent Developmental Therapeutics (DT) strategies that maximally exploit the power of immune-based therapy. Our vision for this proposed T32 is to create a training program and environment that will provide essential skills to clinical trainees while simultaneously providing them with the opportunity to contribute to developing the next generation of cancer therapies. To implement this program, we will draw upon the scientific and translational strengths of the University of Colorado School of Medicine (UCSOM). Indeed, the UCSOM has a strong history of basic immune research (discovery of IL-1 and STING), as well as allergy and autoimmunity research with world- class asthma (National Jewish), and diabetes (Barbara Davis) centers. The UCSOM has provided $20M to launch the Human Immunology and Immunotherapy Initiative (HI3), and has supported the creation of in-house facilities to produce clinical-grade cell therapy products, enabling cutting edge therapies like CAR T-cells. To bridge the bench-to-bedside gap, substantial efforts have been devoted to create advanced, humanized mouse models. Additionally, the UCSOM is a leader in oncology clinical translation with a prestigious DT program, and it was this focus in early DT that allowed us to become leaders in immune and cell therapy. The UCSOM has created a Personalized Medicine Center, designed to facilitate scientific/clinical programs seeking to develop patient-specific therapies. Finally, to link all of the scientific potential in these resources to the delivery of patient care, the medical center has invested over $50M to enhance informatics capabilities enabling data mining and research initiatives towards optimizing clinical decision-making and new therapy development. The sum of the resources outlined above provide the foundation for creating a unique training program, focused on preparing clinical investigators and physician scientists to discover the next generation of immunotherapies. This program will be uniquely tailored to adapt to the specific training requirements of clinical fellows, to guarantee top level research training while maintaining the quality of their core clinical experience. The program will be designated as the Cancer Immunotherapy and Experimental Therapeutics Program (CIETP).

抽象的 癌症仍然是美国发病率和死亡率的一个主要原因，这一发现取得了重大进展 的免疫定向治疗。这是一个快速变化的领域，需要未来的临床研究人员绘制 由于宿主因素起着主导作用，因此所采用的技能与当前的调查和实践截然不同 超越传统的、解剖学驱动的参数。这个拟议的 T32 计划的目标是培训未来 肿瘤学临床提供者和研究人员采用最先进和最有前途的免疫导向和 细胞疗法，通过将这些新需要的技能整合到满足这些独特需求的培训计划中。 新的挑战包括大量正在开发的新药物、新的作用机制、独特的 毒性特征主要包括免疫/自身免疫副作用，以及缺乏患者选择或 这些疗法的预测标记。机会是发明发育疗法（DT） 最大限度地利用免疫疗法的力量的策略。我们对这个拟议的 T32 的愿景是 创建一个培训计划和环境，为临床学员提供基本技能，同时 同时为他们提供为开发下一代癌症做出贡献的机会 疗法。为了实施该计划，我们将利用科学和转化优势 科罗拉多大学医学院 (UCSOM)。事实上，UCSOM 拥有悠久的基础历史。 免疫研究（IL-1 和 STING 的发现），以及与世界各地的过敏和自身免疫研究 类哮喘（国家犹太）和糖尿病（芭芭拉·戴维斯）中心。 UCSOM 已提供 2000 万美元 发起人类免疫学和免疫治疗计划（HI3），并支持创建内部 生产临床级细胞治疗产品的设施，支持 CAR T 细胞等尖端疗法。到 为了弥合实验室与临床之间的差距，我们投入了大量精力来创造先进的、人性化的鼠标 模型。此外，UCSOM 是肿瘤学临床翻译领域的领导者，拥有著名的 DT 项目，并且 正是早期 DT 的这种关注使我们成为免疫和细胞治疗领域的领导者。 UCSOM 有 创建了一个个性化医疗中心，旨在促进寻求发展的科学/临床项目 患者特异性治疗。最后，将这些资源中的所有科学潜力与交付联系起来 患者护理方面，医疗中心已投资超过 5000 万美元来增强信息学能力，支持数据 旨在优化临床决策和新疗法开发的挖掘和研究举措。这 上述资源总和为创建独特的培训计划奠定了基础，重点关注 为临床研究人员和医师科学家发现下一代免疫疗法做好准备。 该计划将专门定制，以适应临床研究员的具体培训要求， 保证顶级研究培训，同时保持核心临床经验的质量。这 计划将被指定为癌症免疫治疗和实验治疗计划（CIETP）。